Search companies

Live

CHIMERIC THERAPEUTICS LIMITED (ASX: CHM)

Health care · News and insights

Price unavailable

Latest CHM announcements

Chimeric Therapeutics Reports Lapse of Performance Rights and Options

2026-10-30 · Health care

CHM: $0.003 +0.00% · MC: $442K

Chimeric Therapeutics reported that performance rights and options lapsed after their conditions were not met or could no longer be satisfied. The company also gave notice of its virtual annual general meeting, scheduled for November, where shareholders will consider a proposed additional share-issue capacity of up to 10% and the re-election of director Phillip Hains.

Updated 2026-10-30 15:23
Share
SourcesNotice of Annual General Meeting/Proxy FormNotification of cessation of securities - CHM
Comments

Chimeric Halts CHM-2101 Trial After Safety Review, Shifts Focus To Preclinical Approach

2026-10-29 · Health care

CHM: $0.003 +0.00% · MC: $442K

Chimeric Therapeutics stopped enrolment and dosing in its CHM-2101 trial after a safety review found the highest tested dose unsafe and trial events triggered the protocol’s stopping rules; the company says it will not progress the treatment in its current form despite preliminary signs of anti-tumour activity. It is proposing a preclinical in vivo CDH17 programme, with animal feasibility work dependent on additional funding, and says cost reductions are expected to lower annualised expenditure by approximately $4 million. The supplied excerpt is truncated and does not include the full cash-flow details.

Updated 2026-10-29 17:19
Share
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments